Now Enrolling Learn More Now Enrolling Learn More Now Enrolling Learn More Latest News Dec 22, 2021 Abeona Therapeutics Issues Letter to Shareholders View Press Release Dec 17, 2021 Abeona Therapeutics Announces Pricing of Public Offering of Common Stock and Warrants View Press Release Dec 16, 2021 Abeona Therapeutics Announces Public Offering of Common Stock and Warrants View Press Release View All Our inspiration Learn More Pipeline Our clinical-stage therapies are designed to deliver functional copies of affected genes to cells using gene transfer technologies. Explore R&D EB-101 In Phase 3 development. Autologous gene-corrected cell therapy for patients with RDEB. Learn More ABO-102 In Phase 1/2 development. One-time, AAV-based gene therapy for patients with Sanfilippo syndrome type A (MPS IIIA). Learn More ABO-101 In Phase 1/2 development. One-time, AAV-based gene therapy for patients with Sanfilippo syndrome type B (MPS IIIB). Learn More Manufacturing at The Elisa Linton Center for Rare Disease Therapies Learn More
